Ventripoint Diagnostics Ltd. Signs Commercial Agreement with LG Consulting Solutions to Support VMS+ Deployment in Northern California

Executive Summary

• Ventripoint Diagnostics Ltd. signed a Memorandum of Understanding and consulting agreement with LG Consulting Solutions to commercialize the VMS+™ AI‑enhanced echocardiography system in Northern California.
• LG Consulting will purchase a VMS+™ system for demonstration, provide economic analysis, clinical implementation support, and develop health‑system business cases.
• The collaboration includes potential revenue sharing on 3D echocardiography processing services and aims to generate measurable clinical and economic value for hospitals and cardiac programs.

Key Details

• Agreement Scope: MoU and consulting agreement covering economic analysis, clinical implementation support, and health‑system business case development for VMS+™ in Sacramento and San Francisco regions.
• System Purchase: LG Consulting Solutions will acquire one VMS+™ system to serve as a demonstration and training platform for targeted healthcare institutions.
• Consulting Services: Outcomes evaluation, implementation planning, and ongoing operational support to help hospitals assess clinical and economic impact of AI‑enhanced echocardiography.
• Revenue Sharing: Potential sharing of revenues derived from 3D echocardiography processing services linked to accounts supported by the consulting engagement.
• Strategic Rationale: Northern California is identified as a high‑value market due to its concentration of leading cardiac centers and focus on improving cardiovascular outcomes and operational efficiency.
• Leadership Quote: Hugh MacNaught, President & CEO, emphasized that the partnership will provide “economic and operational clarity” to accelerate adoption of VMS+™ technology.

Notable Quotes

“Economic and operational clarity are critical to accelerating the adoption of new medical technologies,” – Hugh MacNaught, President & CEO, Ventripoint Diagnostics Ltd.

“Healthcare systems increasingly require clear clinical and economic evidence before adopting new technologies… we will work directly with cardiac programs to develop practical implementation strategies,” – Lori Gallian, Principal, LG Consulting Solutions.